Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06306963 · ClinicalTrials.gov registry record
Prevalence of Gastric Motor Dysfunction and Upper GI Symptoms in Gastric Antral Vascular Ectasias
A clinical trial of Chronic Kidney Disease and Cirrhosis, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT06306963: Recruiting study of Chronic Kidney Disease and Cirrhosis, sponsored by Mayo Clinic.
NCT06306963 is a study of Chronic Kidney Disease and Cirrhosis that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 30 participants, below the 3,207-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06306963, a study of Chronic Kidney Disease and Cirrhosis, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The researchers are trying to find out more about Gastric Antral Vascular Ectasia (GAVE). This is a condition that affects the blood vessels in the stomach, leading to their enlargement and possible bleeding. It can also cause symptoms such as abdominal pain and nausea. By participating in this study, you will help us learn how often these symptoms occur and how they relate to stomach functioning.
Primary Outcome
The Nepean Dyspepsia Index is a 10-item questionnaire that measures dyspepsia problems. Each item is scored from 1-5. 1 = Not at all, 5 = Extremely. Total scores range from 10 - 50, lower scores indicate less dyspepsia problems, higher scores indicate more dyspepsia problems.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Gastric Emptying Breath Test
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-03-22 |
| Est. Completion | 2026-09-01 |
What NCT06306963 shows while recruiting
NCT06306963 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 3,207-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Chronic Kidney Disease appearing as the primary indexed condition, and to 1 intervention - of which Gastric Emptying Breath Test is the first listed.
NCT06306963 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06306963 about?
NCT06306963 is a clinical study titled "Prevalence of Gastric Motor Dysfunction and Upper GI Symptoms in Gastric Antral Vascular Ectasias". The researchers are trying to find out more about Gastric Antral Vascular Ectasia (GAVE). This is a condition that affects the blood vessels in the stomach, leading to their enlargement and possible bleeding. It can also cause symptoms such as abdominal pain and nausea. By participating in this stud...
What is the current status of trial NCT06306963?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2024-03-22. Estimated completion is 2026-09-01.
What conditions does trial NCT06306963 study?
This clinical trial studies the following conditions: Chronic Kidney Disease, Cirrhosis, Gastric Antral Vascular Ectasia.
What interventions are being tested in trial NCT06306963?
The interventions under investigation include: Gastric Emptying Breath Test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06306963?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06306963 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06306963's enrollment target sits among peer trials
30 84th of 101 higher than 17 of 101 other Chronic Kidney Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Kidney Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease: Sympatholysis in CKD
RECRUITING · Phase 2
-
Patient-driven Management of BP in CKD
RECRUITING · Phase 3
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Pivotal Study of the Velocity™ pAVF System
RECRUITING · NA
-
Safety of Short-course of NSAIDs in Pediatric Patients With CKD
RECRUITING · Phase 4
-
Intensive Patient Referral and Education Program Prior to Renal Replacement Therapy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI